Deutsche Bank
LBRX

Deutsche Bank’s LB Pharmaceuticals LBRX Stock Holding History

Deutsche Bank’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$713K Buy
21,972
+6,613
+43% +$194K ﹤0.01% 2577
2026
Q1 		$379K Buy
15,359
+2,061
+15% +$47.5K ﹤0.01% 2718
2025
Q4 		$296K Buy
+13,298
New +$232K ﹤0.01% 2832

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Deutsche Bank's LBRX Position: Q2 2026 in Review

Deutsche Bank increased its LB Pharmaceuticals (LBRX) stake by 43% in Q2 2026, buying an estimated $194K and bringing the position to 21,972 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

Deutsche Bank first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Deutsche Bank held 21,972 shares of LB Pharmaceuticals worth $713K as of Q2 2026.
  • Deutsche Bank bought 6,613 LB Pharmaceuticals shares in Q2 2026, an estimated $194K.
  • LB Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2577 holding.
  • Deutsche Bank first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.